What is Leerink Partnrs’ Estimate for VRDN Q1 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.81) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($1.36) EPS and FY2028 earnings at $1.34 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million.

VRDN has been the topic of a number of other reports. TD Cowen initiated coverage on Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating on the stock. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Royal Bank of Canada lifted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Up 1.6 %

Shares of Viridian Therapeutics stock opened at $19.21 on Wednesday. Viridian Therapeutics has a 1-year low of $11.40 and a 1-year high of $27.20. The firm’s 50-day moving average price is $19.43 and its two-hundred day moving average price is $19.39. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04.

Institutional Trading of Viridian Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Viridian Therapeutics in the 3rd quarter valued at approximately $149,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Viridian Therapeutics during the 3rd quarter worth approximately $208,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock valued at $318,000 after purchasing an additional 2,036 shares during the period. Finally, AlphaCentric Advisors LLC increased its stake in Viridian Therapeutics by 20.0% in the third quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock valued at $341,000 after purchasing an additional 2,500 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.